Franklin, JM; Sharma, RA; Harris, AL; Gleeson, FV; (2016) Imaging oligometastatic cancer before local treatment. The Lancet Oncology , 17 (9) e406-e414. 10.1016/S1470-2045(16)30277-7.

Preview	Text (Accepted manuscript) Franklin_Imaging_oligometastatic_cancer.pdf - Accepted Version Download (255kB) | Preview
Preview	Text (Figure 1) Franklin_Imaging_oligometastatic_cancer_Fig1.pdf - Accepted Version Download (29kB) | Preview
Preview	Text (Figure 2) Franklin_Imaging_oligometastatic_cancer_Fig2.pdf - Accepted Version Download (2MB) | Preview

Abstract

With the advent of novel treatment strategies to help widen the therapeutic window for patients with oligometastatic cancer, improved biomarkers are needed to reliably define patients who can benefit from these treatments. Multimodal imaging is one such option and should be optimised to comprehensively assess metastatic sites, disease burden, and response to neoadjuvant treatment in each disease setting. These features will probably remain important prognostic biomarkers, and are crucial in planning multidisciplinary treatment. There are opportunities to extract additional phenotypic information from conventional imaging, while novel imaging techniques can also reveal specific aspects of tumour biology. Imaging can both characterise and localise the phenotypic heterogeneity of multiple tumour sites. Novel approaches to existing imaging datasets and correlation with tumour biology will be important in realising the potential of imaging to guide treatment in the oligometastatic setting. In this Personal View, we discuss the current status and future directions of imaging before treatment in patients with extracranial oligometastases.

Download activity - last month

Export as XMLJSONCSV

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as XMLJSONCSV

Archive Staff Only

View Item